News
MGTX
13.07
+4.19%
0.53
MeiraGTx: The Market Is Missing The Manufacturing Pivot
Seeking Alpha · 1d ago
Weekly Report: what happened at MGTX last week (0622-0626)?
Weekly Report · 1d ago
Meiragtx Holdings (MGTX) Gets a Buy from Raymond James
TipRanks · 5d ago
Weekly Report: what happened at MGTX last week (0615-0619)?
Weekly Report · 06/22 09:15
Does MeiraGTx (MGTX) Revenue Slide And Lower Institutional Ownership Reframe Its Long-Term Story?
Simply Wall St · 06/21 18:18
MeiraGTx Shareholders Back Board Slate and Auditor Renewal
TipRanks · 06/15 21:59
Weekly Report: what happened at MGTX last week (0608-0612)?
Weekly Report · 06/15 09:15
Weekly Report: what happened at MGTX last week (0601-0605)?
Weekly Report · 06/08 09:14
MeiraGTx posts investor deck outlining late-stage gene therapy pipeline, manufacturing platform
PUBT · 06/05 13:54
Acting FDA head vows to block political interference, Endpoint News says
TipRanks · 06/04 18:16
MeiraGTx publishes corporate deck outlining late-stage gene therapy pipeline, manufacturing platform
PUBT · 06/04 15:43
FDA issues draft guidance to help accelerated cell, gene therapies for patients
TipRanks · 06/02 14:03
Weekly Report: what happened at MGTX last week (0525-0529)?
Weekly Report · 06/01 09:15
MeiraGTx: Buy Rating Reiterated as Pivotal AQUAx2 Path and Dual Launch Opportunities Support Unchanged $20 Price Target
TipRanks · 05/26 10:26
Weekly Report: what happened at MGTX last week (0518-0522)?
Weekly Report · 05/25 09:15
MeiraGTx CEO Alexandria Forbes sells 62,000 shares for $568,540
PUBT · 05/20 01:05
MeiraGTx Holdings plc (NASDAQ:MGTX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Simply Wall St · 05/18 10:39
Weekly Report: what happened at MGTX last week (0511-0515)?
Weekly Report · 05/18 09:15
MeiraGTx Holdings Is Maintained at Outperform by RBC Capital
Dow Jones · 05/15 14:17
MeiraGTx Holdings Price Target Raised to $25.00/Share From $24.00 by RBC Capital
Dow Jones · 05/15 14:17
More
Webull provides a variety of real-time MGTX stock news. You can receive the latest news about Meiragtx Holdings Plc through multiple platforms. This information may help you make smarter investment decisions.
About MGTX
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.